MorphoSys

MorphoSys AG, a German-headquartered Pharmaceutical Preparation Manufacturing company, reported approximately 34,501,000 kg CO2e in total emissions for 2025. This figure comprises about 964,000 kg CO2e from Scope 1, approximately 88,000 kg CO2e from Scope 2 (market-based), and roughly 33,450,000 kg CO2e from Scope 3 emissions.

In 2024, MorphoSys AG's total emissions were approximately 49,295,000 kg CO2e, with Scope 1 emissions at around 1,053,000 kg CO2e, Scope 2 (market-based) at about 114,000 kg CO2e, and Scope 3 at roughly 48,128,000 kg CO2e.

For 2023, the company reported total emissions of approximately 18,856,470 kg CO2e, including Scope 1 emissions of about 101,820 kg CO2e, Scope 2 (market-based) emissions of approximately 1,340 kg CO2e, and Scope 3 emissions of around 18,753,310 kg CO2e.

MorphoSys AG's climate commitments and certain initiatives are cascaded from its ultimate parent, Novartis AG, through a corporate family relationship. For instance, SBTi targets, RE100, and RTZ initiatives are derived from Novartis AG.